Clinical Trial Update: A Randomized, Controlled Trial of Intranasal Oxytocin as an Adjunct to Behavioral Therapy for Autism Spectrum Disorder [Phase 2]

View source ↗

Summary

Phase 2 randomized trial evaluating intranasal oxytocin as an adjunct to behavioral therapy for autism spectrum disorder has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Autism Spectrum Disorder

Drugs mentioned

• intranasal oxytocin (oxytocin)

Snippet

Sponsor: Massachusetts General Hospital | Conditions: Autism Spectrum Disorders | Phase 2 | Status: COMPLETED